Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors. 2014

Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago , 833 South Wood Street, Chicago, Illinois 60612, United States.

Nicotinic acetylcholine receptors (nAChRs) have been investigated for developing drugs that can potentially treat various central nervous system disorders. Considerable evidence supports the hypothesis that modulation of the cholinergic system through activation and/or desensitization/inactivation of nAChR holds promise for the development of new antidepressants. The introductory portion of this Miniperspective discusses the basic pharmacology that underpins the involvement of α4β2-nAChRs in depression, along with the structural features that are essential to ligand recognition by the α4β2-nAChRs. The remainder of this Miniperspective analyzes reported nicotinic ligands in terms of drug design considerations and their potency and selectivity, with a particular focus on compounds exhibiting antidepressant-like effects in preclinical or clinical studies. This Miniperspective aims to provide an in-depth analysis of the potential for using nicotinic ligands in the treatment of depression, which may hold some promise in addressing an unmet clinical need by providing relief from depressive symptoms in refractory patients.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011807 Quinolizines
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000470 Alkaloids Organic nitrogenous bases. Many alkaloids of medical importance occur in the animal and vegetable kingdoms, and some have been synthesized. (Grant & Hackh's Chemical Dictionary, 5th ed) Alkaloid,Plant Alkaloid,Plant Alkaloids,Alkaloid, Plant,Alkaloids, Plant
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D001384 Azetidines
D001392 Azocines
D058990 Molecular Targeted Therapy Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease. Targeted Molecular Therapy,Molecular Targeted Therapies,Molecular Therapy, Targeted,Targeted Molecular Therapies,Targeted Therapy, Molecular,Therapy, Molecular Targeted,Therapy, Targeted Molecular

Related Publications

Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
September 2013, Neuropharmacology,
Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
December 2021, Bioorganic & medicinal chemistry,
Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
May 2013, Bioorganic & medicinal chemistry,
Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
September 2014, Acta neurologica Scandinavica,
Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
December 2022, Brain sciences,
Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
April 2020, Neuropharmacology,
Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
January 2019, Journal of addiction research & therapy,
Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
January 2002, Molecular psychiatry,
Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
February 2018, Bioorganic & medicinal chemistry letters,
Li-Fang Yu, and Han-Kun Zhang, and Barbara J Caldarone, and J Brek Eaton, and Ronald J Lukas, and Alan P Kozikowski
May 2024, Biochemical pharmacology,
Copied contents to your clipboard!